Targeting intratumoral androgens: statins and beyond
While initially effective, androgen deprivation therapy (ADT) is not curative, and nearly all men with advanced prostate cancer will eventually progress to the more resistant, and ultimately lethal form of the disease, so called castration-resistant prostate cancer (CRPC). The maintenance of androge...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2016-09-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/1758834016647962 |
| _version_ | 1818524320373145600 |
|---|---|
| author | Michael T. Schweizer Evan Y. Yu |
| author_facet | Michael T. Schweizer Evan Y. Yu |
| author_sort | Michael T. Schweizer |
| collection | DOAJ |
| description | While initially effective, androgen deprivation therapy (ADT) is not curative, and nearly all men with advanced prostate cancer will eventually progress to the more resistant, and ultimately lethal form of the disease, so called castration-resistant prostate cancer (CRPC). The maintenance of androgens within the prostate cancer microenvironment likely represents one of the key mechanisms by which this transition from hormone-sensitive to CRPC occurs. This can be accomplished either through intratumoral androgen biosynthesis or the active transport of androgens and androgenic precursors into the tumor microenvironment. More recently, preclinical and clinical data supported therapeutic strategies that seek to target these two mechanisms, either through the use of drugs that impair androgen biosynthesis (e.g. inhibiting the steroidogenic enzymes CYP17 and AKR1C3 with abiraterone and indomethacin, respectively) or drugs that inhibit the SLCO transporters responsible for importing androgens (e.g. statins). |
| first_indexed | 2024-12-11T05:55:36Z |
| format | Article |
| id | doaj.art-ba4c712c65c5485fbedf171a949b750c |
| institution | Directory Open Access Journal |
| issn | 1758-8340 1758-8359 |
| language | English |
| last_indexed | 2024-12-11T05:55:36Z |
| publishDate | 2016-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj.art-ba4c712c65c5485fbedf171a949b750c2022-12-22T01:18:41ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83401758-83592016-09-01810.1177/1758834016647962Targeting intratumoral androgens: statins and beyondMichael T. SchweizerEvan Y. YuWhile initially effective, androgen deprivation therapy (ADT) is not curative, and nearly all men with advanced prostate cancer will eventually progress to the more resistant, and ultimately lethal form of the disease, so called castration-resistant prostate cancer (CRPC). The maintenance of androgens within the prostate cancer microenvironment likely represents one of the key mechanisms by which this transition from hormone-sensitive to CRPC occurs. This can be accomplished either through intratumoral androgen biosynthesis or the active transport of androgens and androgenic precursors into the tumor microenvironment. More recently, preclinical and clinical data supported therapeutic strategies that seek to target these two mechanisms, either through the use of drugs that impair androgen biosynthesis (e.g. inhibiting the steroidogenic enzymes CYP17 and AKR1C3 with abiraterone and indomethacin, respectively) or drugs that inhibit the SLCO transporters responsible for importing androgens (e.g. statins).https://doi.org/10.1177/1758834016647962 |
| spellingShingle | Michael T. Schweizer Evan Y. Yu Targeting intratumoral androgens: statins and beyond Therapeutic Advances in Medical Oncology |
| title | Targeting intratumoral androgens: statins and beyond |
| title_full | Targeting intratumoral androgens: statins and beyond |
| title_fullStr | Targeting intratumoral androgens: statins and beyond |
| title_full_unstemmed | Targeting intratumoral androgens: statins and beyond |
| title_short | Targeting intratumoral androgens: statins and beyond |
| title_sort | targeting intratumoral androgens statins and beyond |
| url | https://doi.org/10.1177/1758834016647962 |
| work_keys_str_mv | AT michaeltschweizer targetingintratumoralandrogensstatinsandbeyond AT evanyyu targetingintratumoralandrogensstatinsandbeyond |